Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05298176
Title Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors (COMBINATION)
Acronym COMBINATION
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Amsterdam UMC, location VUmc
Indications
Therapies
Age Groups: adult | senior
Covered Countries NLD


No variant requirements are available.